RxDoctor Payments Data

Kimberly Rines

Nurse Practitioner · West Des Moines, IANPI 1932455052

Payments from drug & device makers

$1,495in general payments, 2019–2025

Across 84 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$521
  • Otsuka America Pharmaceutical, Inc.$331
  • Biohaven Pharmaceuticals, Inc.$94
  • Amgen$90
  • Axsome Therapeutics, Inc.$83
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$63
  • plus $312 from 10 others

What the payments were for

  • Food & beverage$1,495100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,495 in reported general payments places this provider in the 90th percentile of 1,346 nurse practitioner providers in Iowa.

See all nurse practitioner providers in Iowa

Medicare billing

Part B allowed, 2024
$20,827
Medicare patients
106
Services billed
277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuvelityDextromethorphan Hbr/Bupropion17$20,179
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$20,126
Xigduo XrDapaglifloz Propaned/Metformin19$17,805
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$16,096
OzempicSemaglutide17$16,043
XareltoRivaroxaban14$4,791
Lurasidone Hcl11$3,939
Lacosamide18$3,546
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$2,515
Nebivolol Hcl13$1,342
Pregabalin27$1,260
Duloxetine Hcl46$1,248
Memantine Hcl12$1,192
Celecoxib22$966
Potassium Chloride42$695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Axsome Therapeutics, Inc.Auvelity$83$20,17917 claims
Novo NordiskOzempic$56$16,04317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,346 nurse practitioner providers in Iowa.

Other nurse practitioner in West Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →